Status
Conditions
Treatments
About
This study aims to improve the way patients with cardiovascular diseases are informed about their treatment options. It explores methods to support shared decision-making between patients and doctors. In some cases, doctors will take extra time to discuss treatment options in detail. To assess the impact, some patients will be asked to complete questionnaires after their clinic visits.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Established ASCVD
Clinically documented ASCVD includes previous myocardial infarction, acute coronary syndrome, coronary revascularization (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Surgery (CABG)), and other arterial revascularization procedures, ischemic stroke or transient ischemic attack, and peripheral artery disease (from Fontaine stage II). Angina pectoris (stable) without imaging evidence of atherosclerosis does not qualify as ASCVD.
ASCVD unambiguously identified through imaging, includes significant stenosis (>50%) on coronary angiography, computed tomography angiography, or carotic ultrasound. It also includes aortic aneurysms measuring ≥3cm. Only Carotid Intima-Media Thickness measurements (cIMT), Coronary Artery Calcium scoring or abnormal ankle-brachial index scores without evidence of stenosis, do not qualify as ASCVD.
Age 40-80 years (to allow for individual risk predictions with the SMART2 model
Patient attending the Cardiology or Vascular Medicine outpatient clinic
Sufficient understanding of the Dutch language (due to the questionnaires being administered in Dutch).
Written informed consent must be provided. Although the proposed intervention is not subject to the WMO, informed consent is required for the collection and processing of data, including the distribution of questionnaires.
Exclusion criteria
Patients currently participating in other interventional medication studies, or studies that directly affect the therapy plan
Remaining life expectancy of less than 2 years as assessed by a consulting healthcare professional (these patients have no indication for cardiovascular risk management)
Patients for whom individual risk predictions with the SMART2 model are not feasible:
Previous participation in 2-DECIDE
Primary purpose
Allocation
Interventional model
Masking
1,200 participants in 2 patient groups
Loading...
Central trial contact
Elbrich Wempe, MD, PhD candidate; Steven Hageman, Assistant professor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal